PMID- 23044447
OWN - NLM
STAT- MEDLINE
DCOM- 20130228
LR  - 20180813
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 16
IP  - 11
DP  - 2012 Nov
TI  - Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and 
      without tuberculosis.
PG  - 1517-21
LID - 10.5588/ijtld.11.0146 [doi]
AB  - OBJECTIVE: To examine whether hypovitaminosis D is a risk factor for the 
      development of tuberculosis (TB) associated immune reconstitution inflammatory 
      syndrome (IRIS). METHODS: We measured serum 25-hydroxyvitamin D (25D) 
      concentrations in four groups of patients at Mulago Hospital, Kampala, Uganda: 1) 
      patients co-infected with TB and the human immunodeficiency virus (HIV) receiving 
      anti-tuberculosis treatment (HIV+TB+; n = 92) who did and did not develop TB-IRIS 
      after starting antiretroviral treatment (ART), 2) HIV-infected patients without 
      TB (HIV+TB-; n = 20) starting ART, 3) non-HIV-infected individuals with TB 
      (HIV-TB+; n = 27), and 4) those without TB (HIV-TB-; n = 23). RESULTS: The 
      prevalence of optimal 25D levels (>75 nmol/l) was as follows: 59% in HIV+TB+, 65% 
      in HIV+TB-, 63% in HIV-TB+ and 35% in HIV-TB- patients. 25D concentrations 
      decreased during the first 3 months of ART in HIV+TB+ individuals who developed 
      IRIS (P = 0.005) and those who did not (P = 0.002), and in HIV+TB- individuals (P 
      = 0.015); however, 25D concentration in patients who did or did not develop 
      TB-IRIS did not differ. CONCLUSION: The prevalence of optimal vitamin D status 
      was relatively high in HIV-infected patients with and without TB living near the 
      equator. No difference in 25D concentrations was observed between TB-IRIS and 
      non-IRIS. However, 25D concentrations decreased during ART.
FAU - Conesa-Botella, A
AU  - Conesa-Botella A
AD  - Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, 
      Belgium.
FAU - Goovaerts, O
AU  - Goovaerts O
FAU - Massinga-Loembe, M
AU  - Massinga-Loembe M
FAU - Worodria, W
AU  - Worodria W
FAU - Mazakpwe, D
AU  - Mazakpwe D
FAU - Luzinda, K
AU  - Luzinda K
FAU - Mayanja-Kizza, H
AU  - Mayanja-Kizza H
FAU - Colebunders, R
AU  - Colebunders R
FAU - Kestens, L
AU  - Kestens L
CN  - TB IRIS Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal 
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - Antitubercular Agents/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - HIV Infections/*complications/drug therapy/epidemiology
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/epidemiology/*etiology
MH  - Male
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Tuberculosis/*complications/drug therapy/epidemiology
MH  - Uganda/epidemiology
MH  - Vitamin D/analogs & derivatives/blood
MH  - Vitamin D Deficiency/*complications/epidemiology
MH  - Young Adult
FIR - Mascart, F
IR  - Mascart F
FIR - van den Bergh, R
IR  - van den Bergh R
FIR - Locht, C
IR  - Locht C
FIR - Reiss, P
IR  - Reiss P
FIR - Cobelens, F
IR  - Cobelens F
FIR - Ondoa, P
IR  - Ondoa P
FIR - Pakker, N
IR  - Pakker N
FIR - Mugerwa, R
IR  - Mugerwa R
FIR - Pakker, N
IR  - Pakker N
EDAT- 2012/10/10 06:00
MHDA- 2013/03/01 06:00
CRDT- 2012/10/10 06:00
PHST- 2012/10/10 06:00 [entrez]
PHST- 2012/10/10 06:00 [pubmed]
PHST- 2013/03/01 06:00 [medline]
AID - 10.5588/ijtld.11.0146 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2012 Nov;16(11):1517-21. doi: 10.5588/ijtld.11.0146.